Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Naval Group signs contract for four defence and intervention frigates (FDI) for the Royal Swedish Navy

Vinge has advised Naval Group in connection with the negotiations with the Swedish Defence Materiel Administration (FMV) for the procurement of four defence and intervention frigates (FDI) for the Swedish Navy. The contract was signed on 31 August 2026 in Stockholm. Naval Group has been selected as a strategic partner by the Swedish Government to rapidly strengthen and modernise its fleet's capabilities.
September 08, 2026

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Formica

Vinge has advised Formica in conjunction with the acquisition of the CodeIT group, which conducts operations in Norway and Sweden.
September 06, 2026